StreetInsider.com News Articles

Climb Bio (CLYM) PT Raised to $12 at Baird

Fri, 06 Mar 2026 07:10:19 -0500

Baird analyst Colleen Kusy raised the price target on Climb Bio (NASDAQ: CLYM) to $12.00 (from $9.00) while maintaining a Outperform rating.

Climb Bio, Inc. (CLYM) Misses Q4 EPS by 7c

Thu, 05 Mar 2026 17:30:09 -0500

Climb Bio, Inc. (NASDAQ: CLYM) reported Q4 EPS of ($0.26), $0.07 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Climb Bio, Inc. (CLYM) click here.

Form S-8 Climb Bio, Inc.

Thu, 05 Mar 2026 07:30:00 -0500

si-local-file:///var/storage/secattach/20260305/26115137.html

Form S-8 Climb Bio, Inc.

Thu, 05 Mar 2026 07:30:00 -0500

si-local-file:///var/storage/secattach/20260305/26115137.html

Form 10-K Climb Bio, Inc. For: Dec 31

Thu, 05 Mar 2026 07:21:00 -0500

si-local-file:///var/storage/secattach/20260305/26115046.html

Form 10-K Climb Bio, Inc. For: Dec 31

Thu, 05 Mar 2026 07:21:00 -0500

si-local-file:///var/storage/secattach/20260305/26115046.html

Form 8-K Climb Bio, Inc. For: Mar 05

Thu, 05 Mar 2026 07:10:00 -0500

si-local-file:///var/storage/secattach/20260305/26114994.html

Form 8-K Climb Bio, Inc. For: Mar 05

Thu, 05 Mar 2026 07:10:00 -0500

si-local-file:///var/storage/secattach/20260305/26114994.html

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Thu, 05 Mar 2026 07:00:00 -0500

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026

Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026

Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026

Strong financial position with cash runway expected into 2028

WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Thu, 05 Mar 2026 07:00:00 -0500

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026

Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026

Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026

Strong financial position with cash runway expected into 2028

Wedbush Starts Climb Bio (CLYM) at Outperform

Thu, 05 Mar 2026 06:54:52 -0500

Wedbush analyst Laura Chico initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $12.00.

The analyst comments "We are initiating coverage of Climb Bio (CLYM) with an Outperform rating and $12 target. In biotech, being first doesn't always mean being best and we believe budoprutug and CLYM116 carry differentiated profiles versus standard of care. Budoprutug's indication lineup differs versus other anti-CD19's like Uplizna; however, we see good rationale for use in disease settings like pMN. CLYM116 leverages a validated mechanism in IgAN with

Wedbush Starts Climb Bio (CLYM) at Outperform

Thu, 05 Mar 2026 06:54:52 -0500

Wedbush analyst Laura Chico initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $12.00.

Form 4 Climb Bio, Inc. For: Feb 25 Filed by: Thomas Stephen Basil

Fri, 27 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260227/26081530.html

Form 4 Climb Bio, Inc. For: Feb 25 Filed by: Thomas Stephen Basil

Fri, 27 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260227/26081530.html

Form 144 Climb Bio, Inc. Filed by: Thomas Stephen Basil

Wed, 25 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260225/26060537.html

Form 144 Climb Bio, Inc. Filed by: Thomas Stephen Basil

Wed, 25 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260225/26060537.html

Form SCHEDULE 13G Climb Bio, Inc. Filed by: MPM BioImpact LLC

Tue, 17 Feb 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260217/26012725.html

Form SCHEDULE 13G Climb Bio, Inc. Filed by: MPM BioImpact LLC

Tue, 17 Feb 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260217/26012725.html

Form 4 Climb Bio, Inc. For: Feb 12 Filed by: Thomas Stephen Basil

Tue, 17 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260217/26012428.html

Form 4 Climb Bio, Inc. For: Feb 12 Filed by: Thomas Stephen Basil

Tue, 17 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260217/26012428.html

Piper Sandler Starts Climb Bio (CLYM) at Overweight

Fri, 13 Feb 2026 03:47:50 -0500

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Climb Bio (NASDAQ: CLYM) with a Overweight rating and a price target of $23.00.

The analyst comments: "We are initiating coverage on Climb Bio, Inc. (CLYM) with an OW rating and $23 PT where it is developing budoprutug (anti-CD19) across three indications (pMN, ITP, SLE) and CLYM116 (anti-APRIL) in IgAN. Accordingly, CLYM is trading above cash where it has multiple shots on goal to unlock significant value heading into a catalyst-rich mid-2026/2H26. Specifically, budoprutug has high PoS in pMN with Ph1b PoC data demonstrating rapid/durable B-cell depletion, serologic remission, and complete/partial clinical remission

Piper Sandler Starts Climb Bio (CLYM) at Overweight

Fri, 13 Feb 2026 03:47:50 -0500

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Climb Bio (NASDAQ: CLYM) with a Overweight rating and a price target of $23.00.

Form 144 Climb Bio, Inc. Filed by: Thomas Stephen Basil

Thu, 12 Feb 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260212/25992416.html

Form 144 Climb Bio, Inc. Filed by: Thomas Stephen Basil

Thu, 12 Feb 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260212/25992416.html

Climb Bio to Present at Upcoming Investor Conferences

Thu, 05 Feb 2026 07:00:00 -0500

WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.

Guggenheim's Emerging Outlook: Biotech Summit
Format: Fireside Chat
Date: Thursday, February 12, 2026
Time: 3:00 – 3:25 p.m. ET

Oppenheimer 36^th Annual Healthcare Life Sciences Conference
Format: Fireside Chat
Date: Wednesday, February 25, 2026
Time: 1:20 – 1:50 p.m. ET

Leerink Global Healthcare Conference
Format: Fireside Chat
Date: Monday, March 9,